Effectiveness of Intraoperative Cell Salvage in Aseptic Revision Total Hip Arthroplasty.

Completed

• Conditions: Revision of Total Hip Arthroplasty
• Interventions: Procedure: Use of Cell Salvage in revision of total hip arthroplasty

• Registration Number: NCT05237830
• Lead Sponsor: University of Liege

Brief Summary

Intraoperative cell salvage is an important measure of patient blood management but its effectiveness in patients undergoing revision total hip arthroplasty remains unclear. Over the last decade, we have used intraoperative cell salvage systematically in this group of patients. However, since the use of cell salvage has a cost and requires additional resources, we decided to retrospectively investigate its usefulness in this particular indication.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01-01
• Primary Completion: 2021-12-31
• Study Completion: 2022-01-31
• Status Verified: 2022-02
• Study First Submitted: 2022-02-02
• Study First Submitted QC: 2022-02-11
• Last Update Submitted: 2022-02-11
• Study First Posted: 2022-02-14
• Last Update Posted: 2022-02-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

• Eligible patients were adults undergoing elective aseptic revision of hip arthroplasty at the department of orthopedic surgery of the University Hospital of Liege between 01 January 2011 and 31 December 2020.

Exclusion Criteria

• Patients undergoing revision for infection or with local malignancies were excluded from this study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Not Use	Use of Cell Salvage in revision of total hip arthroplasty	Patients in whom the cell saver wasn't effectively used
Use	Use of Cell Salvage in revision of total hip arthroplasty	Patients in whom the cell saver was effectively used

Primary Outcome Measures

Name	Time	Method
Cell savage use	during the surgical procedure	The primary outcome was the proportion of patients in whom the cell saver was effectively used (%)

Secondary Outcome Measures

Name	Time	Method
Aspirated blood	during the surgical procedure	The total volume of blood aspirated into the reservoir (mL)
Re-infused	during the surgical procedure	Total volume of re-suspended blood re-infused (mL)
Hemoglobin	during the surgical procedure	Post-operative hemoglobin level (g/dL)
Allogenic Transfusion	7 days	The need for allogenic blood transfusion (unit)
Fluid	during the surgical procedure	The total amount of fluid infused (mL)

Trial Locations

Locations (1)

CHU de Liège; 🇧🇪 Liège, Belgium